Total C4B deficiency due to gene deletion and gene conversion in a patient with severe infections.

Clin Diagn Lab Immunol

Department of Tissue Typing, Finnish Red Cross Blood Transfusion Service, Helsinki, Finland.

Published: March 2003

Deficiencies of the early components of the classical complement pathway impair the actions of innate and humoral immunity and may lead to increased susceptibility to infections. We have studied the genetic basis of total C4B deficiency in a Finnish patient with recurrent meningitis, chronic fistulas and abscesses. The maternal chromosome carried a four-gene deletion including the C4B gene, and a conversion from C4B to C4A gene was found on the paternal chromosome resulting in complete deficiency of C4B. In the converted C4A gene, mutation screening did not reveal any amino acid changes or prominent mutations, yet a large number of nucleotide variations were found. Further, the patient was heterozygous for structural deficiency of mannan binding lectin (MBL) associating with medium levels of serum MBL. Our data provides new information on the genetic instability of the C4 gene region, and on the association of homozygous C4B deficiency and variant MBL genotype with increased susceptibility to recurrent and chronic infections. Importantly, plasma therapy induced a prompt clinical cure with long-term effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC150532PMC
http://dx.doi.org/10.1128/cdli.10.2.195-201.2003DOI Listing

Publication Analysis

Top Keywords

c4b deficiency
12
total c4b
8
gene conversion
8
increased susceptibility
8
c4a gene
8
gene
6
deficiency
5
c4b
5
deficiency gene
4
gene deletion
4

Similar Publications

Objective: Drug-resistant epilepsy (DRE) poses significant challenges in treatment and management. While seizure-related alterations in peripheral immune players are increasingly recognized, the involvement of the complement system, central to immune function, remains insufficiently explored in DRE. This study aimed to investigate the levels of complement system components and their association with cytokine profiles in patients with DRE.

View Article and Find Full Text PDF

Introduction: Magnetic resonance imaging (MRI)-guided wire localization can be applied to assist to remove suspected breast lesions accurately. This study aimed to evaluate the clinical application value of this technique in Chinese women.

Methods: A total of 126 patients (131 lesions) who had underwent such technique in our hospital from April 2017 to June 2023 were enrolled.

View Article and Find Full Text PDF

Proteomics analysis of coronary atherosclerotic heart disease with different Traditional Chinese Medicine syndrome types before and after percutaneous coronary intervention.

J Tradit Chin Med

June 2024

Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, National Clinical Research Center of Cardiovascular Disease of Traditional Chinese Medicine, Beijing 100000, China.

Article Synopsis
  • The study aimed to understand protein molecular mechanisms behind two Traditional Chinese Medicine (TCM) subtypes of coronary artery disease (CAD) - stagnation and blood stasis syndrome (QS) and deficiency and blood stasis syndrome (QD) - after patients underwent a procedure called percutaneous coronary intervention (PCI).
  • A total of 438 CAD patients (227 with QS and 211 with QD) participated, with serum samples analyzed for protein changes before and after PCI using label-free quantification proteomics.
  • Findings indicated significant biochemical and proteomic changes in both groups post-PCI, with specific proteins and pathways related to inflammation and lipid metabolism being altered, highlighting distinct intervention mechanisms for each CAD subtype.
View Article and Find Full Text PDF

While numerous membrane-bound complement inhibitors protect the body's cells from innate immunity's autoaggression, soluble inhibitors like complement factor I (FI) are rarely produced outside the liver. Previously, we reported the expression of FI in non-small cell lung cancer (NSCLC) cell lines. Now, we assessed the content of FI in cancer biopsies from lung cancer patients and associated the results with clinicopathological characteristics and clinical outcomes.

View Article and Find Full Text PDF

Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic.

Immunobiology

September 2023

Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne NE1 7RU, UK; National Renal Complement Therapeutics Centre, Building 26, Royal Victoria Infirmary, UK; NIHR Newcastle Biomedical Research Centre, Biomedical Research Building, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK. Electronic address:

Complement factor I (FI) is the nexus for classical, lectin and alternative pathway complement regulation. FI is an 88 kDa plasma protein that circulates in an inactive configuration until it forms a trimolecular complex with its cofactor and substrate whereupon a structural reorganization allows the catalytic triad to cleave its substrates, C3b and C4b. In keeping with its role as the master complement regulatory enzyme, deficiency has been linked to immunopathology.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!